United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

John A Zic¹, Weiyun Ai², Oleg E Akilov³, Joi B Carter⁴, Madeleine Duvic⁵, Francine Foss⁶, Michael Girardi⁷, Alejandro A Gru⁸, Ellen Kim⁹, Amy Musiek¹⁰, Elise A Olsen¹¹, Stefan M Schieke¹², Michi Shinohara¹³, Jasmine M Zain¹⁴, Larisa J Geskin¹⁵

Affiliations

¹ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: john.zic@vumc.org.
² Division of Hematology/Oncology, University of California San Francisco, San Francisco, California.
³ Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
⁴ Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
⁵ Department of Dermatology, MD Anderson Cancer Center, Houston, Texas.
⁶ Division of Hematology/Oncology, Yale-New Haven Medical Center, New Haven, Connecticut.
⁷ Department of Dermatology, Yale-New Haven Medical Center, New Haven, Connecticut.
⁸ Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia.
⁹ Department of Dermatology, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania.
¹⁰ Division of Dermatology, Washington University in Saint Louis, St Louis, Missouri.
¹¹ Department of Dermatology, Duke University School of Medicine, Durham, North Carolina.
¹² Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin.
¹³ Department of Dermatology, University of Washington Medical Center, Seattle, Washington.
¹⁴ Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California.
¹⁵ Department of Dermatology, Columbia University Irving Medical Center, New York, New York. Electronic address: ljg2145@cumc.columbia.edu.

PMID: 32305443
PMCID: PMC7161526
DOI: 10.1016/j.jaad.2020.04.049

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

John A Zic et al. J Am Acad Dermatol. 2020 Aug.

. 2020 Aug;83(2):703-704.

doi: 10.1016/j.jaad.2020.04.049. Epub 2020 Apr 16.

Authors

Affiliations

¹ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: john.zic@vumc.org.
² Division of Hematology/Oncology, University of California San Francisco, San Francisco, California.
³ Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
⁴ Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
⁵ Department of Dermatology, MD Anderson Cancer Center, Houston, Texas.
⁶ Division of Hematology/Oncology, Yale-New Haven Medical Center, New Haven, Connecticut.
⁷ Department of Dermatology, Yale-New Haven Medical Center, New Haven, Connecticut.
⁸ Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia.
⁹ Department of Dermatology, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania.
¹⁰ Division of Dermatology, Washington University in Saint Louis, St Louis, Missouri.
¹¹ Department of Dermatology, Duke University School of Medicine, Durham, North Carolina.
¹² Department of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin.
¹³ Department of Dermatology, University of Washington Medical Center, Seattle, Washington.
¹⁴ Division of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California.
¹⁵ Department of Dermatology, Columbia University Irving Medical Center, New York, New York. Electronic address: ljg2145@cumc.columbia.edu.

PMID: 32305443
PMCID: PMC7161526
DOI: 10.1016/j.jaad.2020.04.049

No abstract available

Keywords: COVID-19; Sézary syndrome; cutaneous lymphoma; high-risk; mycosis fungoides.

PubMed Disclaimer

Cited by

Consensus Guidelines for Teledermatology: Scoping Review.
Cummins MR, Ong T, Ivanova J, Barrera JF, Wilczewski H, Soni H, Welch BM, Bunnell BE. Cummins MR, et al. JMIR Dermatol. 2023 May 15;6:e46121. doi: 10.2196/46121. JMIR Dermatol. 2023. PMID: 37632944 Free PMC article. Review.
Clinical outcomes in a cohort of patients with cutaneous T-cell lymphoma and COVID-19.
Runge JS, Bardhi R, Xia Y, Jairath NK, Wilcox RA, Tsoi LC, Tejasvi T. Runge JS, et al. JAAD Int. 2022 Sep;8:52-55. doi: 10.1016/j.jdin.2022.04.008. Epub 2022 May 3. JAAD Int. 2022. PMID: 35529773 Free PMC article. No abstract available.
Primary cutaneous lymphoma and risk for severe COVID-19: a prospective study of 48 cases in Morocco.
Kerrouch H, Khalidi M, Frikh R, Hjira N, Boui M. Kerrouch H, et al. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e512-e514. doi: 10.1111/jdv.18057. Epub 2022 Mar 17. J Eur Acad Dermatol Venereol. 2022. PMID: 35278240 Free PMC article. No abstract available.
Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry.
Sánchez-Velázquez A, Bauer-Alonso A, Estrach T, Vega-Díez D, Garcia-Muret P, Haya L, Peñate Y, Acebo E, Fernández de Misa R, Blanes M, Suh-Oh HJ, Izu R, Silva-Díaz E, Sarriugarte J, Román-Curto C, Botella-Estrada R, Mateu-Puchades A, Prieto-Torres L, Morillas V, Morillo M, Sánchez-Caminero P, Calzado L, Pérez-Ferriols A, Pérez A, Domínguez JD, Navedo M, Muniesa C, Combalia A, Arroyo-Andrés J, Descalzo MA, García-Doval I, Ortiz-Romero PL. Sánchez-Velázquez A, et al. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e624-e626. doi: 10.1111/jdv.17430. Epub 2021 Jul 2. J Eur Acad Dermatol Venereol. 2021. PMID: 34062018 Free PMC article. No abstract available.
Management of primary cutaneous lymphomas during the COVID-19 pandemic.
Mateeva V, Patsatsi A. Mateeva V, et al. Clin Dermatol. 2021 Jan-Feb;39(1):64-75. doi: 10.1016/j.clindermatol.2020.12.014. Epub 2021 Jan 9. Clin Dermatol. 2021. PMID: 33972055 Free PMC article.

See all "Cited by" articles

References

1. Liang W., Guan W., Chen R., et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337. - PMC - PubMed
1. Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis. 2020 doi: 10.1016/j.ijid.2020.03.017. [e-pub ahead of print] - DOI - PMC - PubMed
1. Wang T., Du Z., Zhu F., et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. - PMC - PubMed
1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648. [e-pub ahead of print] - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

Affiliations

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

Authors

Affiliations

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical